Search

Author/Creator Ostrowitzki, S.

1. P06 Concordance of florbetapir (18F) PET and Elecsys® β-Amyloid(1–42) CSF immunoassay in the CREAD (BN29552) study of crenezumab in prodromal-to-mild AD. Issue 8 (August 2019)

Authors:
Grimmer, T.; Rabe, C.; Navarro, M.; Clayton, D.; Manuilova, E.; Peters, O.; Eichenlaub, U.; Smith, J.; Ostrowitzki, S.; Honigberg, L.; Bittner, T.
Journal:
Clinical neurophysiology
Issue:
Volume 130:Issue 8(2019:Aug.)
Page Start:
e148
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

2. P32 Phase III studies of crenezumab in early (prodromal-to-mild) Alzheimers disease (CREAD/CREAD2): Biomarker results. Issue 4 (April 2020)

Authors:
Bittner, T.; Duning, T.; Rabe, C.; Clayton, D.; Quartino, A.; Bohorquez, S. Sanabria; Hu, N.; Rabbia, M.; Shimizu, H.; Eichenlaub, U.; Smith, J.; Honigberg, L.; Selkoe, D.J.; Ostrowitzki, S.
Journal:
Clinical neurophysiology
Issue:
Volume 131:Issue 4(2020:Apr.)
Page Start:
e194
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

3. Results from a phase 1b multiple ascending-dose study of PRX002/RG7935, an Anti-alpha-synuclein monoclonal antibody, in patients with Parkinson's disease. (January 2018)

Authors:
Jankovic, J.; Goodman, I.; Safirstein, B.; Schenk, D.B.; Kinney, G.G.; Koller, M.; Ness, D.K.; Griffith, S.G.; Grundman, M.; Soto, J.; Ostrowitzki, S.; Boess, F.G.; Martin-Facklam, M.; Quinn, J.F.; Issacson, S.H.; Jennings, D.; Omidvar, O.; Ellenbogen, A.
Journal:
Parkinsonism & related disorders
Issue:
Volume 46(2018)Supplement 2
Page Start:
e25
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗